Jennifer Wargo

Jennifer Wargo established that gut microbiome composition determines checkpoint immunotherapy response in melanoma patients, identifying Faecalibacterium and Ruminococcaceae as taxa enriched in responders. Her landmark clinical trials of fecal microbiota transplantation combined with anti-PD-1 therapy demonstrated that modulating the gut microbiome can convert immunotherapy non-responders to responders. Her work on the diet-microbiome-immunity axis has identified high-fiber dietary interventions that enhance immunotherapy efficacy through microbiome-mediated mechanisms.